Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tirabrutinib Maintenance Versus Placebo in Patients With Primary Central Nervous System Lymphoma in Complete Remission: a Randomized Phase II Study (JCOG2104)

NCT06940791 is registered in ClinicalTrials.gov with Kyorin University as lead sponsor.

NCT NCT06940791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06940791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tirabrutinib Maintenance Versus Placebo in Patients With Primary Central Nervous System Lymphoma in Complete Remission: a Randomized Phase II Study (JCOG2104)
Lead sponsor
Kyorin University
Phase
Phase 2
Overall status
Recruiting
Start date
October 6, 2023
Completion date
February 28, 2030
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma